3.90
0.78%
+0.03
Alimera Sciences Inc. stock is currently priced at $3.90, with a 24-hour trading volume of 41,822.
It has seen a +0.78% increased in the last 24 hours and a +11.43% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.90 pivot point. If it approaches the $3.99 resistance level, significant changes may occur.
Alimera Sciences Inc. Stock (ALIM) Financials Data
Alimera Sciences Inc. (ALIM) Revenue 2023
ALIM reported a revenue (TTM) of $80.75 million for the quarter ending December 31, 2023, a +49.19% rise year-over-year.
Alimera Sciences Inc. (ALIM) Net Income 2023
ALIM net income (TTM) was -$20.13 million for the quarter ending December 31, 2023, a -11.18% decrease year-over-year.
Alimera Sciences Inc. (ALIM) Cash Flow 2023
ALIM recorded a free cash flow (TTM) of -$89.79 million for the quarter ending December 31, 2023, a -777.74% decrease year-over-year.
Alimera Sciences Inc. (ALIM) Earnings per Share 2023
ALIM earnings per share (TTM) was -$2.1622 for the quarter ending December 31, 2023, a +16.52% growth year-over-year.
Alimera Sciences Inc. Stock (ALIM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Caligan Partners LP | 10% Owner |
Sep 14 '23 |
Buy |
3.39 |
579,000 |
1,962,810 |
16,835,154 |
Caligan Partners LP | 10% Owner |
Sep 14 '23 |
Sale |
3.39 |
579,000 |
1,962,810 |
16,256,154 |
Morgan Adam | Director |
May 17 '23 |
Buy |
1.70 |
1,401,901 |
2,383,232 |
1,659,654 |
Alimera Sciences Inc. Stock (ALIM) Latest News
New Strong Sell Stocks for March 13th
Zacks Investment Research
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Novavax (NVAX) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Alimera Appoints Maggie A. Pax to Its Board of Directors
GlobeNewswire Inc.
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
About Alimera Sciences Inc.
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Cap:
|
Volume (24h):